Olanzapine Versus Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Phase III, Randomized Controlled Trial Among Patients With Gynecologic Malignancies Receiving Carboplatin and Paclitaxel Every Three Weeks

Authors

S Uppal
A Rolston
Kevin McCool, Corewell Health
A Straubhar
M Brackmann
K Tondo-Stelle
H McLaughlin
O De Bear
C Stroup
J Siedel
R K. Reynolds
K McLean

Document Type

Conference Proceeding

Publication Date

11-2024

Publication Title

Gynecologic Oncology

Volume

190

Issue

Suppl 1

First Page

S392

Comments

Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women's Cancer and Winter Meeting, March 16 - 18, 2024, San Diego, CA

Recommended Citation

Uppal S, Rolston A, McCool K, Straubhar A, Brackmann M, Tondo-Steele K, et al. Olanzapine versus neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting: a phase III, randomized controlled trial among patients with gynecologic malignancies receiving carboplatin and paclitaxel every three weeks. Gynecol Oncol. 2024 Nov;190(Suppl 1):S392. doi:10.1016/j.ygyno.2024.07.581

DOI

10.1016/j.ygyno.2024.07.581